ReviewCurrent oncology reports2026
Imaging as a Driver of Multidisciplinary Decision-making in Neuroendocrine Neoplasms: A Targeted Evidence Synthesis.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewNeuroendocrine neoplasms (NENs) are heterogeneous tumors requiring accurate staging and disease characterization to guide treatment, including eligibility for peptide receptor radionuclide therapy (PRRT). Imaging—particularly somatostatin receptor (SSTR) PET/CT—plays a key role in multidisciplinary tumor boards (MTBs). This review evaluates the impact of imaging on clinical decision-making in NENs. RECENT
findingsSeven studies assessing imaging within MTBs were included, with four providing comparable management change data (517 cases). Imaging-attributable management changes ranged from 36% to 59%, with a pooled estimate of 49% (95% CI 35–63%; I² = 78%). Imaging most commonly influenced decisions on PRRT eligibility, surgical planning, liver-directed therapies, and adjustments to systemic treatment. Imaging significantly impacts multidisciplinary decision-making in NENs, altering management in approximately half of cases. Despite heterogeneity across studies, findings support the central role of SSTR PET/CT in guiding treatment. Prospective studies with standardized definitions and patient-centered outcomes are needed to better establish clinical benefit.
Indexed as
Identifiers
42010049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.